Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02367040 | Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-3) | completed | Phase 3 | 458 | BayerINDUSTRY | 37 | Oct 14, 2025 | clinicaltrials |
| NCT07202052 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202065 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202078 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202091 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT03057054 | Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 3 | 173 | Children's Oncology GroupNETWORK | 2 | Oct 6, 2025 | clinicaltrials |
| NCT05556720 | Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial(BOOST-IC) | active not recruiting | Phase 3 | 960 | Monash UniversityOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT02201459 | Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients(PETALs) | completed | Phase 3 | 200 | Hospices Civils de LyonOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04551053 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | terminated | Phase 3 | 177 | Incyte CorporationINDUSTRY | 19 | Oct 2, 2025 | clinicaltrials |
| NCT07203352 | Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL | recruiting | Phase 3 | 154 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04229979 | Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2(REGAL) | active not recruiting | Phase 3 | 127 | Sellas Life Sciences GroupINDUSTRY | 10 | Oct 1, 2025 | clinicaltrials |
| NCT01650701 | A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma(RELEVANCE) | completed | Phase 3 | 1,030 | The Lymphoma Academic Research OrganisationOTHER | 8 | Sep 25, 2025 | clinicaltrials |
| NCT07187960 | Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma | not yet recruiting | Phase 3 | 228 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07181239 | Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients | not yet recruiting | Phase 3 | 280 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT01241708 | Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma((Mel/MelVel)) | completed | Phase 3 | 148 | Hackensack Meridian HealthOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07178457 | Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance(BeCALM) | not yet recruiting | Phase 3 | 84 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Sep 17, 2025 | clinicaltrials |
| NCT02716233 | A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents(CAALL-F01) | active not recruiting | Phase 3 | 2,044 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT06947967 | Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype | recruiting | Phase 3 | 224 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07157514 | Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML | not yet recruiting | Phase 2 / Phase 3 | 306 | Actinium PharmaceuticalsINDUSTRY | 0 | Sep 10, 2025 | clinicaltrials |
| NCT01863550 | Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 3 | 1,087 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Sep 8, 2025 | clinicaltrials |
| NCT07152041 | Newly-diagnosed Pediatric Ph-positive B-ALL Protocol(CAMS-Ph+ B-ALL) | recruiting | Phase 3 | 150 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 2 | Sep 3, 2025 | clinicaltrials |
| NCT02136134 | Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 498 | Janssen Research & Development, LLCINDUSTRY | 15 | Aug 29, 2025 | clinicaltrials |
| NCT00278408 | Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma | completed | Phase 3 | 700 | German High-Grade Non-Hodgkin's Lymphoma Study GroupOTHER | 4 | Aug 26, 2025 | clinicaltrials |
| NCT06855810 | Newly-diagnosed Pediatric T-cell ALL Protocol(CCCG-TALL-2025) | recruiting | Phase 2 / Phase 3 | 610 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 2 | Aug 26, 2025 | clinicaltrials |
| NCT06882057 | Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol(CCCG-LR-B-ALL) | recruiting | Phase 2 / Phase 3 | 3,000 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 2 | Aug 26, 2025 | clinicaltrials |
| NCT02195479 | A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma | completed | Phase 3 | 706 | Janssen Research & Development, LLCINDUSTRY | 24 | Aug 22, 2025 | clinicaltrials |
| NCT07075016 | Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy(EVOLVE 1) | recruiting | Phase 3 | 227 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 16 | Aug 19, 2025 | clinicaltrials |
| NCT06387069 | A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia | recruiting | Phase 3 | 316 | HutchmedINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT02066454 | Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs(MYELAXAT) | completed | Phase 3 | 108 | University Hospital, GrenobleOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT05481151 | A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV | active not recruiting | Phase 3 | 111 | PharmaEssentiaINDUSTRY | 2 | Aug 13, 2025 | clinicaltrials |
| NCT03159897 | FIL Study on ABVD DD-DI as Upfront Therapy in HL. | completed | Phase 3 | 500 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT05210790 | A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera(VERIFY) | active not recruiting | Phase 3 | 293 | Protagonist Therapeutics, Inc.INDUSTRY | 20 | Aug 7, 2025 | clinicaltrials |
| NCT06033586 | Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera(THRIVE) | active not recruiting | Phase 3 | 46 | Protagonist Therapeutics, Inc.INDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT00002462 | RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease | active not recruiting | Phase 3 | 615 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Aug 5, 2025 | clinicaltrials |
| NCT00005584 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma | active not recruiting | Phase 3 | 1,649 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Aug 5, 2025 | clinicaltrials |
| NCT00049595 | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma | completed | Phase 3 | 552 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 13 | Aug 5, 2025 | clinicaltrials |
| NCT00379041 | Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma | active not recruiting | Phase 3 | 1,158 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Aug 5, 2025 | clinicaltrials |
| NCT03575351 | A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas(TRANSFORM) | completed | Phase 3 | 184 | CelgeneINDUSTRY | 12 | Aug 3, 2025 | clinicaltrials |
| NCT07082452 | A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction(SEVENAZA) | not yet recruiting | Phase 3 | 262 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT03112174 | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)(SYMPATICO) | completed | Phase 3 | 366 | Pharmacyclics LLC.INDUSTRY | 17 | Jul 22, 2025 | clinicaltrials |
| NCT06464991 | A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)(FUMANBA-03) | recruiting | Phase 3 | 240 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06580223 | Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma | not yet recruiting | Phase 3 | 530 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT02763319 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)(B-MIND) | completed | Phase 2 / Phase 3 | 453 | Incyte CorporationINDUSTRY | 23 | Jul 17, 2025 | clinicaltrials |
| NCT03897127 | Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics | active not recruiting | Phase 3 | 882 | University of UlmOTHER | 2 | Jul 17, 2025 | clinicaltrials |
| NCT01996865 | Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.(MAGNIFY) | completed | Phase 3 | 503 | CelgeneINDUSTRY | 3 | Jul 10, 2025 | clinicaltrials |
| NCT07059156 | Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL | recruiting | Phase 2 / Phase 3 | 50 | Shanxi Bethune HospitalOTHER | 1 | Jul 10, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 14, 2025source: clinicaltrials